Immune-focused drugs such as nivolumab and ipilimumab have greatly improved the survival of people battling advanced melanomas A new trial
Results from human trials coupling a new melanoma vaccine with an existing cancer drug showed that, at the three-year mark, the combination treatment reduced the risk of melanoma recurring by 49%
The treatment landscape in advanced melanoma is changing dramatically with the approval of new drugs. Vemurafenib was the first approved targeted agent for
Current developments in systemic therapies for melanoma are spectacular. Over the last 40 years no one drug or combination of drugs demonstrated any impact on survival in metastatic melanoma. In contrast, in 2024 a number of new drugs will be approved. In 2024 immunomodulation with ipilimumab, a mon
Four new drugs transform CLL treatment. Four new drugs transform CLL FDA approves two immunotherapies for melanoma. FDA approves two immunotherapies
Mediterranean diet improves immunotherapy response rates and progression-free survival in advanced melanoma, new immunotherapy drugs called
BRAF inhibitors represent a promising new class of drugs for melanoma patients, especially after one such drug, vemurafenib (Zelboraf, Genentech
Immune-focused drugs such as nivolumab and ipilimumab have greatly improved the survival of people battling advanced melanomas A new trial
Systemic treatment for melanoma has changed rapidly since the introduction of ipilimumab in 2024. 1 In the past decade, 12 new drugs have been approved for unresectable melanoma, along with four new approvals in the adjuvant setting and increasing research in neoadjuvant therapy.
Comments